I am in this for every part of this tech, being taken out by a...

I am in this for every part of this tech, being taken out by a predator.
MRX, MRI. / Contrast. Multiple cancer types, where ever the NPs can get to.

Just because MRX has taken a back seat for now, does not remove its forward value from a takeover perspective.

We have shown safety in human use in our phase 1 trial. A pretty big deal for going forward with.

A market whipped this in the med tech sphere from here to 200m mc, previously.
Ask Why ?

While MRI offers that faster route to commercial hardware, the MRX has substantial legs for a predator to peruse, as well the third party applications. At a micro cap, the valuation needs to float with the forwards agenda after the impatient have left the building, without the covid delays that trapped the phase 1 trial.

Bring on say a partnering with the HER2 phase 2 trial, and if i was calling the shots, start pushing other cancer types / partnering ??

A lot to like, speculatively at this end of the med tech pricing, regards to how markets can swing when a registry is flushed, and replaced with a more competent management to push us forwards.

Gamble well. Not investment advice.